The role of CaMKII in diabetic heart dysfunction

Heart Failure Reviews

Volumn 20, Issue 5, 2015, Pages 589-600

  Daniels, Lorna ^a   Bell, James R ^b   Delbridge, Lea M D ^b   McDonald, Fiona J ^a   Lamberts, Regis R ^a   Erickson, Jeffrey R ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CaMKII; Diabetes mellitus; Diabetic heart dysfunction; Exercise; Heart failure

Indexed keywords

AUTOCAMTIDE 2 RELATED INHIBITORY PEPTIDE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA; CALCIUM ION; N ACETYLGLUCOSAMINE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

AEROBIC EXERCISE; APOPTOSIS; ARTICLE; ATRIAL FIBRILLATION; CALCIUM TRANSPORT; CARBOHYDRATE SYNTHESIS; CARDIOVASCULAR DISEASE; CYCLING; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC HEART DYSFUNCTION; DISEASE ASSOCIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME MODIFICATION; EXERCISE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HIGH INTENSITY INTERVAL TRAINING; HUMAN; INCIDENCE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RUNNING; SWIMMING; THERAPY EFFECT; WALKING; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; HEART CONTRACTION; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; DIABETIC CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; HUMANS; MICE; MYOCARDIAL CONTRACTION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84938747898     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-015-9498-3     Document Type: Article

References (153)

1. Whiting DR, Guariguata L, Weil C, Shaw J (2011) IDF diabetes atlas: global estimate of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94:311–321
2. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103:137–149
3. Kannel WB, McGee DL (1979) Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 2:120–126
4. Marwick TH (2006) Diabetic heart disease. Heart 92:296–300
5. Hayat SA, Patel B, Khattar RS, Malik RA (2004) Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci 107:539–557
6. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595–602
7. Malmberg K, Ryden L (1987) Myocardial infarction in patients with diabetes mellitus. Eur Heart J 9:259–264
8. Adeghate E (2004) Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem 18:1–5
9. Simone G, Devereux RB, Howard BV (2010) Diabetes and incident heart failure in hypertensive and normotensive participants of the strong heart study. J Hypertens 28:353–360
10. Asmal AC, Leary WP, Thandroyen F (1980) Diabetic heart disease. S Afr Med J 57:788–790
11. Rawal S, Manning P, Katare R (2014) Cardiovascular microRNAs: as modulators and diagnostic biomarkers of diabetic heart disease. Cardiovasc Diabetol 13:1–24
12. Bugger H, Abel ED (2014) Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57:660–671
13. Hasenfuss G (1997) Calcium handling proteins in the failing human heart. Basic Res Cardiol 92:87–93
14. Hasenfuss G (1998) Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res 37:279–289
15. Hasenfuss G, Pieske B (2002) Calcium cycling in congestive heart failure. JMCC 34:951–969
16. 2+ regulation in heart failure. Physiology 21:380–387
17. Ather S, Rrespress JL, Li Na L, Wehrens XHT (2013) Alterations in ryanodine receptors and related proteins in heart failure. Biochim Biophys Acta 1832:2425–2431
18. 2+ handling in heart failure. Circ Res 113:690–708
19. Fabiato A, Fabiato F (1979) Calcium and cardiac excitation-contraction coupling. Ann Rev Physiol 41:473–484
20. Bers DM (2008) Excitation-contraction coupling and cardiac contractile force. In: Excitation contraction coupling and cardiac contractile force, 2nd edn. Springer, Netherlands, pp 203–244
21. Bers DM (2002) Cardiac excitation-contraction coupling. Nature 415:198–205
22. Fabiato A (1983) Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol 245:1–14
23. Stern MD, Capogrossi MC, Lakatta EG (1988) Spontaneous calcium release from the sarcoplasmic reticulum in myocardial cells: mechanisms and consequences. Cell Calcium 9:247–256
24. Lukyanenko V, Gyorke I, Gyorke S (1996) Regulation of calcium release by calcium inside the sarcoplasmic reticulum in ventricular myocytes. Eur J Physiol 432:1047–1054
25. Solaro RJ, Rarick HM (1998) Troponin and tropomyosin proteins that switch on and tune in the activity of cardiac myofilaments. Circ Res 83:471–480
26. Bers DM (2000) Calcium fluxes involved in control of cardiac myocyte contraction. Circ Res 87:275–281
27. Zhang X, Chen C (2012) A new insight of mechanisms, diagnosis and treatment of diabetic cardiomyopathy. Endocrine 41:398–409
28. Lopaschuk GD, Tahiliani AG, Vadlamudi RV, Katz S, McNeill JH (1983) Cardiac sarcoplasmic reticulum function in insulin-or carnitine-treated diabetic rats. Am J Physiol Heart Circ Physiol 245:969–976
29. Flarsheim CE, Grupp IL, Matlib MA (1996) Mitochondrial dysfunction accompanies diastolic dysfunction in diabetic rat heart. Am J Physiol Heart Circ Physiol 271:192–202
30. Ye G, Metreveli NS, Ren J, Epstein PN (2003) Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 52:777–783
31. Ye G, Metreveli NS, Donthi RV, Xia S, Xu M, Carlson EC, Epstein PN (2004) Catalase protects cardiomyocyte function in models of type 1 and type 2 diabetes. Diabetes 53:1336–1343
32. Kralik PM, Ye G, Metreveli NS, Shem X, Epstein PN (2005) Cardiomyocyte dysfunction in models of type 1 and type 2 diabetes. Cardiovasc Toxicol 5:285–292
33. Bugger H, Abel ED (2009) Rodent models of diabetic cardiomyopathy. Dis Model Mech 2:454–466
34. Belke DD, Swanson EA, Dillmann WH (2004) Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 53:3201–3208
35. 2+] transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes 55:608–615
36. 2+ leak promotes atrial fibrillation in mice. J Clin Invest 119:1940–1951
37. 2=- leak in human cardiac pathology. Circ 128:970–981
38. 2+) leak in human ischaemic dilated cardiomyopathy. Eur J Heart Fail 16:1292–1300
39. 2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res 106:1134–1144
40. 2+ release. Circ Res 92:904–911
41. Maier LS, Bers DM (2002) Calcium, calmodulin and calcium-calmodulin kinase II: heartbeat to heartbeat and beyond. J Moll Cell Cardiol 34:919–939
42. 2+/calmodulin-dependent protein kinase II in cardiac hypertrophy and heart failure. Cardiovas Res 63:476–486
43. Braun AP, Schulman H (2005) The multifunctional calcium/calmodulin-dependent protein kinase: from form to function. Annu Rev Physiol 57:417–445
44. Lin CR, Kapiloff MS, Durgerian S, Tatemoto K, Russo AF, Hanson P et al (1987) Molecular cloning of a brain-specific calcium-calmodulin-dependent protein kinase. Proc Natl Acad Sci USA 84:5962–5966
45. 2+/calmodulin-dependent protein kinase type II by a bifunctional calmodulin-binding peptide. Proc Natl Acad Sci USA 85:4991–4995
46. 2+/calmodulin-dependent protein kinase II. J Biol Chem 263:18145–18151
47. Smith MK, Colbran RJ, Bricky DA, Soderling TR (1992) Functional determinants in the autoinhibitory domain of calcium/calmodulin-dependent protein kinase II. Role of His282 and multiple basic residues. J Biol Chem 267:1761–1768
48. 2+/calmodulin-dependent protein kinase by autophosphorylation: ATP modulates production of an autonomous enzyme. Proc Natl Acad Sci USA 83:9497–9501
49. Meyer T, Hanson PI, Stryer L, Schulman H (1992) Calmodulin trapping by calcium-calmodulin-dependent protein kinase. Science 256:1199–1201
50. 2+ oscillations. Science 279:227–230
51. Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV et al (2008) A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133:462–474
52. Erickson JR, He JB, Grumbach IM, Anderson ME (2011) CaMKII in the cardiovascular system: sensing redox states. Physiol Rev 91:889–915
53. Zhang DM, Chai Y, Erickson JR, Brown JH, Bers DM, Lin YF (2014) Intracellular signaling mechanism responsible for modulation of sarcolemmal ATP-sensitive potassium channels by nitric oxide in ventricular cardiomyocytes. J Physiol 592:971–990
54. 2+/calmodulin- dependent protein kinase II (CaMKII). J Biol Chem 28:19458–19465
55. 2+/calmodulin-dependent protein kinase II: the role of structure and autoregulation in cellular function. Ann Rev Biochem 71:473–510
56. Erickson JR (2014) Mechanisms of CaMKII activation in the heart. Frontiers in Pharm Res 59:1–5
57. Torres CR, Hart GW (1984) Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc. J Biol Chem 259:3308–3317
58. Zachara NE, Hart GW (2004) O-GlcNAc a sensor of cellular state: the role of nucleocytoplasmic glycosylation in modulating cellular function in response to nutrition and stress. Biochem Biophys Acta 1673:13–28
59. Zachara NE, Hart GW (2006) Cell signaling, the essential role of O-GlcNAc! Biochem Biophys Acta 1761:599–617
60. Hart GW (1997) Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins. Annu Rev Biochem 66:315–335
61. Wells L, Whalen SA, Hart GW (2003) A regulatory post-translational modification. Biochem Biophys Res Commun 302:435–441
62. Comer FI, Hart GW (1999) O-GlcNAc and the control of gene expression. Biochem Biophys Acta 1473:161–171
63. McLarty JL, Marsh SA, Chatham JC (2013) Post-translational protein modification by O-linked N-acetyl-glucosamine: its role in mediating the adverse effects of diabetes on the heart. Life Sci 92:621–627
64. Chatham JC, Marchase RB (2010) The role of protein O-linked B-N-acetylglucosamine in mediating cardiac stress response. Biochem Biophys Acta 1800:57–66
65. Medford HM, Chatham JC, Marsh SA (2012) Chronic ingestion of a western diet increases O-linked-B-N-acetylglucosamine (O-GlcNAc) protein modification in the rat heart. Life Sci 90:23–24
66. Taylor RP, Parker GJ, Hazel MW, Soesanto Y, Fuller W, Yazzie MJ et al (2008) Glucose deprivation stimulates O-GlcNAC modification of proteins through upregulation of O-linked N-acetylglucosaminyltransferase. J Biol Chem 283:6050–6057
67. Zou L, Zhu-Maldin Z, Marchase RB, Paterson AJ, Liu J, Yang Q, Chatham JC (2012) Glucose deprivation-induced increase in protein O-GlcNAcylation in cardiomyocytes is calcium dependent. J Biol Chem 287:34419–34431
68. Hu Y, Belke D, Suarez J, Swanson E, Clark R, Hoshijima M et al (2005) Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. Circ Res 96:1006–1013
69. Yokoe S, Ashai M, Takeda T, Otsu K, Taniguchi N, Miyoshi E et al (2010) Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy. Glycobio 20:1217–1226
70. Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K et al (2013) Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycolysation. Nature 502:372–376
71. Liu J, Marchase RB, Chatham JC (2007) Glutamine-induced protection of isolated rat heart from ischemia/reperfusion injury is mediated via the hexosamine biosynthesis pathway and increase protein O-GlcNAc levels. JMCC 42:177–185
72. Zachara NE, O’Donnell N, Cheng WD, Mercer JJ, Marth JD, Hart GW (2004) Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress: a survival response in mammalian cells. J Biol Chem 279:30133–30142
73. Zou L, Yang S, Hu S, Chaudry IH, Marchase RB, Chatham JC (2007) The protective effects of PUGNAc on cardiac function after trauma-hemorrhage are mediated via increase protein O-GlcNAc levels. Shock 27:402–408
74. Zou L, Yang S, Champattanachai V, Hu S, ChauDRY IH, Marchase RB et al (2009) Glucosamine improves cardiac function following trauma-hemorrhage by increase protein O-GlcNAcylation and attenuation of NF-(kappa) b signaling. Am J Physiol Heart Circ Physiol 296:515–523
75. Anderson ME, Brown JH, Bers DM (2011) CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol 51:468–473
76. Swaminathan PD, Purohit A, Hund TJ, Anderson ME (2012) Calmodulin-dependent protein kinase II: linking heart failure and arrhythmias. Circ Res 110:1661–1677
77. Couchonnal LF, Anderson ME (2008) The role of calmodulin kinase II in myocardial physiology and disease. Physiology 23:151–159
78. Witcher DR, Kovacs RJ, Schulman H, Cefali DC, Jones LR (1991) Unique phosphorylation site on the cardiac ryanodine receptor regulates calcium channel activity. J Biol Chem 266:11144–11152
79. 2+/calmodulin dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res 94:61–70
80. Simmerman HK, Collins JH, Theibert JL, Wegener AD, Jones LR (1986) Sequence analysis of phospholamban. Identification of phosphorylation sites and two major structural domains. J Biol Chem 261:13333–13341
81. Brittsan AG, Kranias EG (2000) Phospholamban and cardiac contractile function. J Mol Cell Card 32:2131–2139
82. 2+/CaM-dependent kinases: from activation to function. Annu Rev Pharmacol Toxicol 41:471–505
83. 2+/calmodulin-dependent protein kinase in failing and nonfailing human hearts. Cardiovas Res 42:254–261
84. 2+/calmodulin-dependent protein kinase in failing and nonfailing human myocardium. Circ Res 84:713–721
85. 2+/calmdoulin-dependent protein kinase II improves contractility in human failing myocardium. Circ Res 107:1150–1161
86. Zhang T, Maier LS, Dalton ND, Miyamoto S, Ross J, Donald M et al (2003) The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ Res 92:912–919
87. 2+ release is prolonged in nonfailing myocardium of diabetic patients. Mol Cell Biochem 308:141–149
88. Lamberts RR, Lingam SJ, Wang H, Bollen IAE, Hughes G, Galvin IF et al (2014) Impaired relaxation despite upregulated calcium-handling pro in atrial myocardium from type 2 diabetic patients with preserved ejection fraction. Cardiovasr diabetol 13:72
89. Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48:1–9
90. Jay D, Hitomi H, Griendling KK (2006) Oxidative stress and diabetic cardiovascular complications. Free Rad Bio Med 40:183–192
91. Luo M, Guan X, Luczak ED, Lang D, Kutschke W, Gao Z et al (2013) Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J Clin Invest 123:1262–1274
92. Purohit A, Rokita AG, Guan X, Chen B, Koval OM, Voigt N et al (2013) Oxidized CaMKII triggers atrial fibrillation. Circulation 128:1748–1757
93. Song Y, Shryock JC, Belardinelli L (2008) An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol 294:2031–2039
94. Swaminathan PD, Purohit A, Soni S, Voigt N, Singh MV, Glukhov AV et al (2011) Oxidized CaMKII causes cardiac sinus node dysfunction in mice. J Clin Invest 121:3277–3288
95. 2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circ 125:2059–2070
96. Weiss JN, Garfinkel A, Karaguezian HS, Chen P, Qu Z (2010) Early afterdepolarizations and cardiac arrhythmias. Heart rhythm 7:1891–1899
97. Westenbrink BD, Edwards AG, McCulloch AD, Brown JH (2013) The promise of CaMKII inhibition for heart disease: preventing heart failure and arrhythmias. Expert Opin Ther Targets 17:889–903
98. Luczak ED, Anderson ME (2014) CaMKII oxidative activation and the pathogenesis of cardiac disease. JMCC 73:112–116
99. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towhin J, Vincent GM (1996) Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps and future directions. The SADS foundation task force on LQTS. Circ 94:1996–2012
100. ++/calmodulin-depenent protein kinase, decreases early afterdepolarization in rabbit heart. J Pharm Exp Tech 287:996–1006
101. Venetucci LA, Trafford AW, O’Neill SC, Eisner DA (2008) The sarcoplasmic reticulum and arrhythmogenic calcium release. Cardiovas Res 77:285–292
102. Wright SC, Schellenberger U, Ji L, Wang H, Larrick JW (1997) Calmodulin-dependent protein kinase II mediates signal transduction in apoptosis. FASEBJ 11:843–849
103. 2+ pathway to antagonize Wnt/B-catening signaling. Mol Cell Bio 23:131–139
104. 2+-induced p38 MAP kinase activation. EMBO Rep 5:161–166
105. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T et al (1994) JNKI: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025–1037
106. Dhanasekaran DN, Reddy EP (2008) JNK signaling in apoptosis. Oncogen 27:6245–6251
107. Zhu W, Woo AY, Yang D, Cheng H, Crow MT, Xiao R (2007) Activation of CaMKIIdeltaC is a common intermediate of diverse death stimuli-induced heart muscle cell apoptosis. J Biol Chem 282:10833–10839
108. 2+ overload causes mitochondrial-dependent apoptosis in ventricular myocytes. Circ Res 97:1009–1017
109. Joiner MA, Koval OM, Jingdong Li, He JB, Allamargot C, Gao Z et al (2012) CaMKII determines mitochondrial stress responses in heart. Nature 491:269–273
110. Maisch B, Alter P, Pankuweit S (2011) Diabetic cardiomyopathy-fact or fiction? Herz 36:102–115
111. Cai L, Kang YJ (2001) Oxidative stress and cardiomyopathy: a brief review. Cardiovasc Toxicol 1:181–193
112. Ren J, Gintant GA, Miller RE, Davidoff AJ (1994) High extracellular glucose impairs cardiac E-C coupling in a glycolysation-dependent manner. Am J Physiol 273:2876–2883
113. Clark RJ, McDonough PM, Swanson E, Trost SU, Suzuki M, Fukuda M et al (2003) Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem 278:44230–44237
114. Cai L, Li Wei, Wang G, Guo L, Jiang Y, Kang YJ (2002) Hyperglycemia-induced apoptosis in mouse myocardium- mitochondrial cytochrome c-mediated caspase-3 activation pathway. Diabetes 51:1938–1948
115. Backlund T, Palojoki E, Saraste A, Eriksson A, Finckenberg P, Kyto V et al (2004) Sustained cardiomyocytes apoptosis and left ventricular remodeling after myocardial infarction in experimental diabetes. Diabetologia 47:325–330
116. Zhang R, Kooh MSC, Wu Y, Yang Y, Grueter CE, Ni G et al (2005) Calmodulin kinase II inhibition protects against structural heart disease. Nat Med 11:409–417
117. Backs J, Backs T, Neef S, Kreusser MM, Lehmann LH, Patrick DM et al (2009) The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci USA 106:2342–2347
118. 2+/calmodulin-dependent kinase II in the transition from the pressure overload-induced cardiac hypertrophy to heart failure in mice. J Clin Invest 119:1230–1240
119. Cheng J, Xu L, Lai D, Guilbert A, Lim HJ, Keskanokwong T et al (2012) CaMKII inhibition in heart failure, beneficial, harmful or both. Am J Physiol 302:1453–1465
120. 2+/calmodulin-dependent protein kinase (CaMK) in excitation-contraction coupling in the heart. Cardiovas Res 73:631–640
121. 2+/calmodulin-dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12H cells. Biochem Biophys Res Commun 181:968–975
122. Ishida A, Kameshita I, Okuno S, Kitani T, Fujisawa H (1995) A novel specific and potent inhibitor of calmodulin-dependent protein kinase II. Biochem Biophys Res Commun 212:806–812
123. Sag CM, Wadsack DP, Khabbazzadeh S, Abesser M, Grefe C, Neumann K et al (2009) Calcium/calmodulin-dependent protein kinase II contributes to cardiac arrhythmogenesis in heart failure. Circ Heart Fail 2:664–675
124. Pellicena P, Schulamn H (2014) CaMKII inhibitors: from research tools to therapeutic agents. Front Pharma 5:1–10
125. 2+ release synchronicity in a mouse model of diabetic cardiomyopathy. Circ Res 105:527–536
126. Chudyk A, Petrella RJ (2011) Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta analysis. Diabetes Care 34:1228–1237
127. Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ (2001) Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta analysis of controlled trials. JAMA 286:1218–1227
128. Cuff DJ, Meneilly GS, Martin A, Ignaszewski A, Tidesley HD, Frohlich JJ (2003) Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. Diabetes Care 26:2977–2982
129. Bordenave S, Brandou F, Manetta J, Fedou C, Mercier J, Brun JF (2007) Effects of acute exercise on insulin sensitivity, glucose effectiveness and disposition index in type 2 diabetic patients. Diabetes Metab 34(250):257
130. Brassard P, Legault S, Garneau C, Bogaty P, Dumesnil JG, Poirier P (2007) Normalization of diastolic dysfunction in type 2 diabetics after exercise training. Med Sci Sports Exerc 39:1896–1901
131. Lamberts S, Van Laethem C, Van Acker K, Calders P (2008) Influence of combined exercise training on indices of obesity, diabetes and cardiovascular risk in type 2 diabetes patients. Clin Rehabil 22(483):492
132. Malfatto G, Facchini M, Bragato R, Branzi G, Sala L, Leonetti G (1996) Short and long term effects of exercise training on the tonic autonomic modulation of heart rate variability after myocardial infarction. Eur Heart J 17:532–538
133. Oldrige NB, Guyatt GG, Fischer ME, Rimm AA (1988) Cardiac rehabilitation after myocardial infarction: combined experience of randomized clinical trials. J Am Med Assoc 260:945–950
134. Philip A, Ades MD (2001) Cardiac rehabilitation and secondary prevention of coronary heart disease. N Engl J Med 345:892–902
135. Taylor RS, Brown A, Ebrahim S, Joliffe J, Noorani H, Rees K et al (2003) Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 116:682–692
136. Banzer JA, Maguire TE, Kennedy CM, O’Malley CJ, Balady GJ (2004) Results of cardiac rehabilitation in patients with diabetes mellitus. Am J Cardiol 93:81–84
137. Boukhris M, Tomasello D, Khanfir R, Elhadj Z, Terra AW, Marza F et al (2015) Impact of cardiac rehabilitation on ventricular repolarization indexes and ventricular arrhythmias in patients affected by coronary artery disease and type 2 diabetes. Heart Lung 44:199–204
138. Horden MD, Dunstan DW, Prins JB, Baker MK, Fiatarone Singh MA, Coombes JS (2012) Exercise prescription for patients with type 2 diabetes and pre-diabetes: a position statement from exercise and sport science Australia. J Sci Med Spor 15:25–31
139. Boule NG, Kenny GP, Haddad E, Wells GA, Sigal RJ (2003) Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in type 2 diabetes mellitus. Diabetologia 46:1071–1081
140. Gibala MJ, Little JP, van Essen M, Wilkin GP, Burgomaster KA, Safdar A et al (2006) Short-term sprint interval versus traditional endurance training: similar initial adaptations in human skeletal muscle and exercise performance. J Physiol 575:901–911
141. Hood MS, Little JP, Tarnopolsky MA, Myslik F, Gibala MJ (2011) Low-volume interval training improves muscle oxidative capacity in sedentary adults. Med Sci Sports Exerc 43:1849–1856
142. Little JP, Safdar A, Wilkin GO, Tarnopolsky MA, Gibala MJ (2010) A practical model of low-volume high-intensity interval training induces mitochondrial biogenesis in human skeletal muscle: potential mechanisms. J Physiol 588:1011–1022
143. Bloomgarden ZT (1999) American Diabetes Association annual meeting—diabetes and obesity. Diabetes Care 23:118–124
144. Linke SE, Gallo LC, Norman GJ (2011) Attrition and adherence rates of sustained vs. intermittent exercise interventions. Ann Behav Med 42:197–209
145. Holten MK, Zacho M, Gaster M, Juel C, Wojtaszewski JF, Dela F (2004) Strength training increases insulin-mediated uptake, GLUT4 content, and insulin signaling in skeletal muscle in patients with type 2 diabetes. Diabetes 53:294–305
146. Yang Z, Scott CA, Mao C, Tang J, Farmer AJ (2013) Resistance exercise versus aerobic exercise for type 2 diabetes: a systematic review and meta-analysis. Sports Med 44:487–499
147. Sigal RJ, Kenny GP, Boule NG, Wells GA, Prud’homme D, Fortier M et al (2007) Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 147:357–369
148. Church TS, Blair SN, Cocreham S, Johannsen N, Johnson W, Kramer K et al (2010) Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. JAMA 304:2253–2262
149. 2+ cycling by phosphorylation of CaMKII and Thr-17 of phospholamban. J Mol Cell Cardiol 43:354–361
150. Kaurstad G, Alves MN, Kemi OJ, Rolim N, Hoydal MA, Wisloff H et al (2012) Chronic CaMKII inhibition blunts the cardiac contractile response to exercise training. Eur J App Physiol 112:579–588
151. Bennett CE, Virginia L, Shearer J, Belke DD (2013) Exercise training mitigates aberrant cardiac protein O-GlcNAcylation in streptozotocin-induced diabetic mice. Life Sci 92:657–663
152. Belke DD (2011) Swim-exercised mice show a decreased level of protein O-GlcNAcylation and expression of O-GlcNAc transferase in the heart. J App Physiol 111:157–162
153. Cox EJ, Marsh SA (2013) Exercise and diabetes have opposite effects on the assembly and O-GlcNAc modification of the mSin3A/HDAC1/2 complex in the heart. Cardiovas Diabetol 12:101